No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
wuxixdc.comNo one on the platform currently holds 2268.HK.
No tracked institution reports a position in 2268.HK as of their last filing.
No one on the platform has traded 2268.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.7% | 63.3% | — | — | — | |
| Rev. Growth % | 46.7% | 128.1% | ||||
| Profit Margin % | 24.9% | 19.6% | ||||
| Free Cash Flow Margin % | 10.7% | -2.2% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.5B | +44.8% | $1.78 | $1.56–$2.04 | — | 15 |
| 2027 | $12.8B | +33.9% | $2.54 | $2.16–$3.23 | — | 13 |
| 2028 | $16.6B | +30.1% | $3.36 | $3.16–$3.59 | — | 8 |
| 2029 | $19.1B | +14.7% | $4.15 | $3.91–$4.44 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-24 | $0.68 | $0.59 | -13.0% |
| 2026-03-23 | $0.69 | $0.68 | -1.6% |
| 2025-08-20 | $0.61 | $0.57 | -6.6% |
| 2025-03-25 | $0.48 | $0.52 | +9.0% |
| 2024-08-20 | $0.25 | $0.38 | +53.7% |
| 2024-03-25 | $0.11 | $0.12 | +10.0% |
| $17.00 |
| -0.70% |
| $63.7B |
| — |
| 2607.HKShanghai Pharmaceuticals Holding Co., Ltd | $11.05 | -0.81% | $64.1B | — |
| 2617.HKTransThera Sciences (Nanjing). Inc. | $9.66 | +0.99% | $3.8B | — |
Source: Financial Modeling Prep · peers by sector/industry